<DOC>
	<DOCNO>NCT02377401</DOCNO>
	<brief_summary>Zanamivir potent highly selective inhibitor influenza virus neuraminidase . Intravenous ( IV ) zanamivir develop treatment hospitalize patient influenza , especially patient may greatest need parenteral influenza antiviral agent . This study pharmacokinetic ( PK ) study evaluate safety/tolerability pharmacokinetic profile IV zanamivir 300 milligram ( mg ) 600 mg Chinese healthy subject . Subjects randomize receive either 300 mg 600 mg IV zanamivir single dose follow repeat dose every 12 hour ( h ) 5 day . Subjects contact return study center follow-up visit , 7 day last dose withdrawal study . Total number subject plan enrollment 24 approximately 10 subject complete dose critical assessment dose cohort . The total duration study approximately 6 week screen follow-up .</brief_summary>
	<brief_title>Pharmacokinetics Zanamivir After Single Repeated Dose Infusion Administration Healthy Chinese Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination laboratory test . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 1924 kilogram per meter square ( kg/m^2 ) ( inclusive ) . BMI = ( weight kg ) / ( height meter ) ^2 . A female subject eligible participate nonchildbearing potential childbearing potential negative pregnancy test determine urine human chorionic gonadotropin ( hCG ) test . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication completion followup visit . Capable give write informed consent , include compliance requirement restriction list consent form . Alanine amino transferase ( ALT ) bilirubin &lt; =1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent ) . Based single average correct QT ( QTc ) value triplicate ECGs obtain brief recording period : QTc &lt; 450 millisecond ( msec ) . Criteria Based Upon Medical Histories Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK medical monitor , contraindicate participation . Criteria Based Upon Diagnostic Assessments A positive prestudy hepatitis B surface antigen ( HBsAg ) positive hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . A positive test syphilis . Pregnant female determine positive urine hCG test screen prior dosing . Have creatinine clearance &lt; =80 milliliter per minute ( mL/min ) ( CockcroftGault ) . Estimated creatinine clearance rate ( eCCr ) = ( 140 Age ) x Mass ( Kg ) x Constant/Serum Creatinine micromole per liter ( Î¼mol/L ) , constant 1.23 men 1.04 woman . Other Criteria Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) prior first dose day current study . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>Zanamivir</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>intravenous</keyword>
</DOC>